Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CLXT · Entity 6658 | Chief Executive Officer | June 15, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date June 15, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,300 |
Reported balance
After 2018-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-15 · Sale · Disposed 14,700 · Balance 181,300 F1: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2: Includes 166,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 29,400 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person.
F2: Includes 166,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 29,400 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2018 Filed Jun 15, 2018 22:28 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 14,700 | $19.49 | $286,503.00 |
DisclosureSEC source: 0001127602-18-021072 · form4.xml · nonDerivative · entry 1 Tripodi Federico A. · CIK 0001712282 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,300 F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2 · balance_after: Includes 166,600 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 29,400 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.